Literature DB >> 28654427

DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors.

Leanne de Kock1, Tatjana Terzic, W Glenn McCluggage, Colin J R Stewart, Patricia Shaw, William D Foulkes, Blaise A Clarke.   

Abstract

Ovarian Sertoli-Leydig cell tumors (SLCTs) are uncommon sex cord-stromal tumors associated with both germ-line and somatic DICER1 mutations, the frequency of which has varied widely in different studies (0% to 62.5%). The current World Health Organization Classification includes 3 histologic types of SLCTs (well-differentiated, moderately differentiated, and poorly differentiated); heterologous elements and/or retiform patterns may be present in moderately and poorly differentiated neoplasms. We investigated the frequency of DICER1 mutations in a series of 38 ovarian tumors initially diagnosed as SLCTs, and explored whether identified mutations were associated with specific morphologic features. Specialist pathology review performed blinded to molecular results confirmed 34 tumors to be SLCTs (22 moderately differentiated, 8 poorly differentiated; 4 well-differentiated), while the remaining 4 neoplasms were considered not to represent SLCTs. Of the 34 cases diagnosed as SLCTs, 30 (88%) harbored ≥1 DICER1 mutation. All 30 moderately differentiated/poorly differentiated SLCTs contained mutations, but we did not find deleterious DICER1 mutations in the 4 well-differentiated SLCTs. Our study reports the highest DICER1 mutation frequency to date in SLCTs, with 100% of moderately differentiated and poorly differentiated tumors being DICER1-mutated. This suggests that DICER1 mutation may be a defining feature of these neoplasms. Although the number of cases is limited, well-differentiated SLCTs appear to be DICER1-independent. Moderately differentiated and poorly differentiated SLCT components often coexist with each other and form part of a spectrum, while well-differentiated SLCTs usually occur in pure form, suggesting that fundamentally, these represent 2 separate and independent tumor types with a different pathogenesis. We suggest that all patients with ovarian SLCTs undergo germ-line DICER1 mutation testing.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28654427     DOI: 10.1097/PAS.0000000000000895

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  24 in total

1.  Clinical Characteristics and Mutation Analyses of Ovarian Sertoli-Leydig Cell Tumors.

Authors:  Zhen Yuan; Xiao Huo; Dezhi Jiang; Mei Yu; Dongyan Cao; Huanwen Wu; Keng Shen; Jiaxin Yang; Ying Zhang; Huimei Zhou; Yao Wang
Journal:  Oncologist       Date:  2020-08-11

2.  Expanding the spectrum of dicer1-associated sarcomas.

Authors:  Mikako Warren; Matthew C Hiemenz; Ryan Schmidt; Jared Shows; Jennifer Cotter; Stephanie Toll; David M Parham; Jaclyn A Biegel; Leo Mascarenhas; Rachana Shah
Journal:  Mod Pathol       Date:  2019-09-19       Impact factor: 7.842

3.  Case - A tale of two boys: An atypical cause of pubertal precocity.

Authors:  Kosalan Akilan; Karmon Janssen; Armando Lorenzo; Fadi Zu'bi; Hal Scherz; Martin A Koyle
Journal:  Can Urol Assoc J       Date:  2020-07       Impact factor: 1.862

4.  A family with Sertoli-Leydig cell tumour, multinodular goiter, and DICER1 mutation.

Authors:  M Haley; P Bindal; A McAuliffe; J Vredenburgh
Journal:  Curr Oncol       Date:  2019-06-01       Impact factor: 3.677

Review 5.  Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.

Authors:  Ugo Testa; Eleonora Petrucci; Luca Pasquini; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2018-02-01

6.  Significantly greater prevalence of DICER1 alterations in uterine embryonal rhabdomyosarcoma compared to adenosarcoma.

Authors:  Leanne de Kock; Ju-Yoon Yoon; Blaise A Clarke; William D Foulkes; Maria Apellaniz-Ruiz; Dylan Pelletier; W Glenn McCluggage; Colin J R Stewart; Brendan C Dickson; Marjan Rouzbahman
Journal:  Mod Pathol       Date:  2020-01-03       Impact factor: 7.842

Review 7.  Imaging of DICER1 syndrome.

Authors:  R Paul Guillerman; William D Foulkes; John R Priest
Journal:  Pediatr Radiol       Date:  2019-10-16

Review 8.  Ovarian neoplasms of childhood.

Authors:  Shailee V Lala; Naomi Strubel
Journal:  Pediatr Radiol       Date:  2019-10-16

9.  Embryonal rhabdomyosarcoma of the uterine corpus: a clinicopathological and molecular analysis of 21 cases highlighting a frequent association with DICER1 mutations.

Authors:  Jennifer A Bennett; Zehra Ordulu; Robert H Young; Andre Pinto; Koen Van de Vijver; Eike Burandt; Pankhuri Wanjari; Rajeev Shah; Leanne de Kock; William D Foulkes; W Glenn McCluggage; Lauren L Ritterhouse; Esther Oliva
Journal:  Mod Pathol       Date:  2021-05-20       Impact factor: 7.842

Review 10.  Spectrum of DICER1 Germline Pathogenic Variants in Ovarian Sertoli-Leydig Cell Tumor.

Authors:  Elisa De Paolis; Rosa Maria Paragliola; Paola Concolino
Journal:  J Clin Med       Date:  2021-04-23       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.